Results 151 to 160 of about 19,943,678 (222)

Cancer-Associated Thrombosis: A Taiwanese Perspective on Therapeutic Options with Focus on Non-Vitamin K Antagonist Oral Anticoagulants. [PDF]

Acta Cardiol Sin, 2023
Shao YY, Ho CL, Chang CS, Chang CL, Lee JK, Lin HJ, Hsiao HH, Chao TC, Lin CY, Liaw CC.   +9 more
europepmc   +1 more source

Proton pump inhibitor co-therapy in patients receiving non-vitamin K antagonist oral anticoagulants: current evidence, gastrointestinal bleeding prevention, and clinical considerations. [PDF]

Front Cardiovasc Med
Kim DH, Kim Y, Kim MH, Kang J, Park J.
europepmc   +1 more source

Association of high-estimated glomerular filtration rate with the severity of ischemic stroke during non-vitamin K antagonist oral anticoagulants therapy: a nationwide cohort study. [PDF]

Front Neurol, 2023
Kang MK, Lee D, Oh MS, Lee JS, Jeong HY, Shin JH, Yoon BW, Park JM.   +7 more
europepmc   +1 more source

Reperfusion thrombolytic therapy for ischemic stroke in patients on non-vitamin K antagonist oral anticoagulants: study protocol of a phase II randomized clinical trial. [PDF]

Trials
Karaszewski B, Jabłoński B, Gąsecki D, Szczyrba S, Wyszomirski A.   +4 more
europepmc   +1 more source

Cardiovascular outcomes in patients with atrial fibrillation concomitantly treated with antiarrhythmic drugs and non-vitamin k antagonist oral anticoagulants. [PDF]

Europace, 2023
Wu VC, Wang CL, Huang YC, Tu HT, Huang YT, Huang CH, Chen SW, Kuo CF, Hung KC, Chang SH.   +9 more
europepmc   +1 more source

Comparative Renal Outcomes and Effectiveness of Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Nonvalvular Atrial Fibrillation: Insights from Real-World Data. [PDF]

Medicina (Kaunas)
Tongkate K, Chantrarat T, Boonmuang P, Saelim W, Ruenroengbun N, Kongwatcharapong J.   +5 more
europepmc   +1 more source

New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events

, 2015
Ymer H Mekaj,1,2 Agon Y Mekaj,3 Shkelzen B Duci,4 Ermira I Miftari5 1Institute of Pathophysiology, Faculty of Medicine, University of Prishtina, 2Department of Hemostasis and Thrombosis, National Blood Transfusion Center of Kosovo, 3Clinic of ...
Mekaj AY, Miftari EI, Duci SB, Mekaj YH
core  

Safety of off-label dose reduction of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. [PDF]

Br J Clin Pharmacol, 2023
van den Dries CJ, Pajouheshnia R, van den Ham HA, Souverein P, Moons KGM, Hoes AW, Geersing GJ, van Doorn S.   +7 more
europepmc   +1 more source

Non-Vitamin K Antagonist Oral Anticoagulants for Thromboembolic Prevention in Patients with Atrial Fibrillation and Concomitant Mitral Stenosis: A Retrospective Observational Study. [PDF]

Acta Cardiol Sin
Liu HT, Lee HL, Wang YC, Chou SC, Chou CC.   +4 more
europepmc   +1 more source

Non-Vitamin K Antagonist Oral Anticoagulants versus Low Molecular Weight Heparin for Cancer-Related Venous Thromboembolic Events: Individual Patient Data Meta-Analysis. [PDF]

Cancers (Basel), 2023
Yau CE, Low CE, Ong NY, Rana S, Chew LJR, Tyebally SM, Chai P, Yeo TC, Chan MY, Lee MX, Tan LL, Koo CY, Lee ARYB, Sia CH.   +13 more
europepmc   +1 more source